Furthermore, it opens doors for exploring PPARγ as a potential therapeutic target for interventions aimed at modulating senescence-associated processes in ACO–a condition marked by mixed features of both asthma and COPD, known for its increased severity. The gene discussed is PPARG; the disease is asthma.